Polygenic Risk Score Shows Promise in Predicting Future Breast Cancer in Early-Stage Patients
A new study reveals that a 313-gene polygenic risk score can predict the future risk of breast cancer in women with early-stage diagnoses, offering a promising tool for personalized treatment planning.
Recent research indicates that a blood test utilizing a polygenic risk score (PRS) based on 313 genetic markers (SNPs) can help forecast the likelihood of developing breast cancer in women diagnosed with early-stage conditions such as ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Published in ancer Epidemiology, Biomarker & Prevention , this study analyzed data from over 2,300 women, including 2,169 with DCIS and 185 with LCIS.
The study found notable associations between PRS scores and breast cancer risk. Women with DCIS in the highest risk quartile were more than twice as likely (2.03 times) to develop cancer in the opposite breast (contralateral) compared to those in the lowest quartile. However, this score did not significantly correlate with new cancer in the same breast (ipsilateral). Conversely, among LCIS patients, higher PRS scores were linked with a greater risk of cancer in the same breast, increasing the risk by over two times.
Family history further influenced these risks, with women having a familial background of breast cancer experiencing more than a threefold increase in ipsilateral cancer risk when their PRS was high. Excluding those who underwent mastectomy and radiotherapy amplified this risk to four times.
The findings suggest that PRS can be a valuable tool in personalizing treatment plans. By integrating genetic risk scores with traditional diagnostic information, clinicians could better identify women at heightened risk who might benefit from additional preventive therapies, potentially reducing unnecessary treatments.
While promising, the researchers acknowledge limitations, such as the specific design of PRS for invasive disease rather than in-situ conditions and the relatively small cohort of LCIS cases. Further research is essential to validate these results across diverse populations and to assess additional genetic factors.
Overall, the study advances the potential of genomic tools in enhancing breast cancer risk assessment and guiding more tailored therapeutic decisions, ultimately aiming to improve patient outcomes.
source: https://medicalxpress.com/news/2025-09-polygenic-score-future-breast-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Weight-Loss Medications Significantly Reduce Alcohol Consumption, Study Finds in Ireland
Weight-loss drugs like liraglutide and semaglutide have been shown to reduce alcohol consumption by nearly two-thirds over four months, offering promising insights into their broader health benefits. Read more about this innovative research from Ireland.
Increased Risk of Physician Burnout Associated with Incomplete Staffing Levels
A recent study links incomplete staffing levels with higher burnout rates among physicians, emphasizing the importance of proper team composition to improve doctor well-being.
Innovative Ultrasound Helmet Facilitates Non-Invasive Deep Brain Stimulation
A novel ultrasound helmet enables non-invasive, targeted stimulation of deep brain structures, promising advances in neuroscience research and treatment of neurological disorders without surgery.
Virtual Reality Effectively Reduces Anxiety During Interventional Cardiac Procedures
Virtual reality has been shown to significantly reduce anxiety and stabilize vital signs in patients undergoing coronary angiography, offering a promising non-drug approach to improve cardiovascular procedure experiences.